Press Releases August 3, 2026 04:05 PM

Seer to Report Second Quarter 2026 Financial Results on August 11, 2026

Seer, Inc. Schedules Q2 2026 Financial Results Announcement and Conference Call

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
SEER

Seer, Inc., a Nasdaq-listed company specializing in advanced proteomics technology, announced it will report its second quarter 2026 financial results on August 11, 2026, accompanied by a webcasted conference call for investors and analysts. The company highlights its leadership in proteomics with proprietary products aimed at research applications.

Seer to Report Second Quarter 2026 Financial Results on August 11, 2026
SEER
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Seer, Inc. will report its Q2 2026 financial results on August 11, 2026.
  • Management will host a live webcast conference call to discuss the financial results.
  • Seer offers a Proteograph Product Suite integrating nanoparticles, instrumentation, and software for deep proteomic analysis, serving the research segment.

REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2026 on Tuesday, August 11, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.

About Seer
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer's Proteograph Product Suite integrates proprietary engineered nanoparticles, automation instrumentation, optimized consumables, and advanced analytical software. Seer's products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

Media Contact:
Patrick Schmidt
pr@seer.bio 

Investor Contact:
Marissa Bych
investor@seer.bio 


Risks

  • Results may not meet investor expectations, potentially impacting stock price negatively.
  • As Seer's products are for research use only and not diagnostic, regulatory or market adoption risks exist in proteomics and biotech sectors.
  • The announcement does not provide forward-looking guidance, creating uncertainty about future financial performance.

More from Press Releases

The Elmet Group to Deploy Strategic Capital to Strengthen U.S. and Allied Tungsten Supply Chain Sep 14, 2026 Department of War Makes Landmark $450 Million Committed Investment in The Elmet Group to Secure America’s Tungsten Supply Chain Sep 14, 2026 BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients Sep 14, 2026 Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company Sep 14, 2026 NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer Sep 14, 2026